Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CDC25B | P30305 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.51 |
| ▸ | CDC25C | P30307 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681837 | 0.90 | TSHR (0.68) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| SCHEMBL18526159 | 0.88 | TSHR (0.66) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| SCHEMBL21845577 | 0.85 | TSHR (0.61) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| SCHEMBL7741671 | 0.83 | TSHR (0.59) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| Phthalic Acid SCHEMBL29064574 | 0.82 | TSHR (0.62) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| SCHEMBL954118 | 0.82 | TSHR (0.58) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| SCHEMBL14958374 | 0.81 | TSHR (0.66) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| SCHEMBL578128 | 0.80 | TSHR (0.77) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| SCHEMBL2137984 | 0.79 | TSHR (0.63) | TSHRCDC25BALDH1A1HSD17B10CDC25A | |
| SCHEMBL26107048 | 0.79 | TSHR (0.63) | TSHRCDC25BALDH1A1HSD17B10CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2173719-A1 | 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003867-A1 | 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003867-A1 | 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012138-A1 | 4-IMIDAZOLINES | TAAR1, TAAR5, GPR119 | TSHR 23/4885CDC25B 1297/4885ALDH1A1 612/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TSHR 222/4885CDC25B 512/4885ALDH1A1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.